Monday, November 23, 2026

OQP BioM's 'Oregovomab' Is the Only Korean Candidate Among 12 Phase 3 Ovarian Cancer Candidates

Input
2026-10-01 16:02:15
Updated
2026-10-01 16:02:15
Provided by OQP BioM.

[Financial News] Oregovomab, an ovarian cancer treatment being developed by an OQP BioM subsidiary, is emerging as a candidate with a differentiated target in the global Phase 3 race. The drug is a CA-125-targeting antibody, while antibody-drug conjugates (ADCs) have become the mainstream approach in ovarian cancer drug development.
According to OQP BioM on the 1st, its subsidiary CanariaBio's oregovomab was included among 12 ovarian cancer drug candidates in Phase 3 development featured in the September 2026 issue of the international journal Nature Reviews Drug Discovery.
The group includes treatments being developed by global pharmaceutical companies such as Eli Lilly, AstraZeneca, Merck & Co. (MSD outside the U.S. and Canada), and GlaxoSmithKline (GSK). The company said oregovomab is the only candidate from a Korean company.
Seven of the 12 candidates are ADCs, while oregovomab is the only CA-125-targeting antibody. In other words, it has chosen a different path from its global competitors not only in development stage but also in target and mechanism of action.
The treatment setting also differs. While many candidates target recurrent ovarian cancer or maintenance therapy, oregovomab is being developed as a first-line treatment for patients with early-stage ovarian cancer, in combination with existing anticancer drugs.
Meanwhile, the ovarian cancer treatment market itself is expanding. According to an analysis by Clarivate cited by the company, the ovarian cancer treatment market across seven major countries, including the United States, Europe, and Japan, is projected to grow from $3.92 billion in 2025 to $7.37 billion in 2034.
A company official said, "Oregovomab is a candidate distinguished by its target and treatment stage within the late-stage ovarian cancer pipeline, which is centered on ADCs. Through clinical development, we will continue to assess its potential as a treatment option differentiated from existing therapies." 


[email protected] Kim Kyung-ah Reporter